WEEKLY EPIDEMIOLOGY BULLETIN

NATIONAL SURVEILLANCE UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

Weekly Spotlight

Antimicrobial Resistance (Part 3)



Drug resistance in HIV, tuberculosis and malaria

HIV drug resistance (HIVDR) is caused by changes in the HIV genome that affect the ability of antiretroviral (ARV) drugs to block the replication of the virus. HIVDR can either be transmitted at the time of infection or acquired because of inadequate

adherence to treatment or drug-drug interactions. HIVDR can lead to increased HIV infections and HIV-associated morbidity and mortality. WHO recommends that countries routinely implement HIVDR surveys to inform the selection of optimal ARV drug regimens for HIV prevention and treatment.

Tuberculosis (TB) is a major contributor to antimicrobial resistance. Multidrug-resistant tuberculosis (MDR-TB) is a form of TB caused by bacteria that do not respond to isoniazid and rifampicin, the two most effective first-line TB drugs. MDR-TB is treatable and curable by using second-line drugs, but these medicines are expensive and toxic, and in some cases more extensive drug resistance can develop. TB caused by bacteria that do not respond to the most effective second-line TB drugs can leave patients with very limited treatment options. MDR-TB is therefore a public health crisis and threat to health security. Only about 2 in 5 people with drug resistant TB accessed treatment in 2022.

The emergence of drug-resistant parasites is a major threat to malaria control. Artemisinin-based combination therapies (ACTs) are the recommended first-line treatment for uncomplicated Plasmodium falciparum malaria and are used by most malaria endemic countries. Emergence of partial resistance to artemisinin and/or partner drugs in ACTs makes selecting the right treatment more challenging and requires close monitoring. In the Greater Mekong Subregion, partial resistance to artemisinin or a partner drug has been confirmed in several countries since 2001. In the WHO Eastern Mediterranean Region, resistance to a partner drug, sulfadoxine-pyrimethamine, led in some countries to treatment failure requiring a change to another ACT. In Africa, mutations linked to artemisinin partial resistance have been observed in several countries. ACTs that have been tested remain efficacious, but further spread of resistance could be a major public health challenge and improved surveillance is vital.

Taken from WHO website on 24/December/2024 https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

EPI WEEK 50



Syndromic Surveillance

Accidents


Violence

Pages 2-4



Class 1 Notifiable Events

Page 5



COVID-19

Page 6



Influenza

Page 7



Dengue Fever

Page 8




Research Paper

Page 9

SENTINEL SYNDROMIC SURVEILLANCE

Sentinel Surveillance in Jamaica





Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.

Table showcasing the **Timeliness of Weekly Sentinel Surveillance** Parish Reports for the Four **Most Recent Epidemiological Weeks -**47 to 50 of 2024

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. Reports submitted after 3 p.m. are considered late.

KEY:

Yellow- late submission on **Tuesday**

Red - late submission after **Tuesday**


Epi week	Kingston and Saint Andrew	Saint Thomas	Saint Catherine	Portland	Saint Mary	Saint Ann	Trelawny	Saint James	Hanover	Westmoreland	Saint Elizabeth	Manchester	Clarendon
						20	024						
47	On	On	On	On	On	On	On	On	On	On	On	On	On
47	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
48	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time
49	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time
50	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time	On Time


REPORTS FOR SYNDROMIC SURVEILLANCE

UNDIFFERENTIATED FEVER

Temperature of $>38^{\circ}C$ /100.40F (or recent history of fever) with or without an obvious diagnosis or focus of infection.










INVESTIGATION **REPORTS-** Detailed Follow



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued







FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



40 35 30 Number of visits 25 20 15 10

Weekly Visits to Sentinel Sites for Fever and Neurological Symptoms 2023 and 2024 vs. Weekly Threshold: Jamaica

Epidemiological week

11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47


2024 Alert Threshold Epidemic Threshold

FEVER AND HAEMORRHAGIC

Temperature of $>38^{\circ}C$ $/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.



Weekly visits to Sentinel Sites for Fever and Haemorrhagic 2023 and 2024 vs Weekly Threshold; Jamaica




FEVER AND JAUNDICE

Temperature of $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.

The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.



Fever and Jaundice cases: Jamaica, Weekly Threshold vs Cases 2023 and 2024









INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events



HOSPITAL **ACTIVE** SUR VEILLANCE-30 sites. Actively pursued






ACCIDENTS

Any injury for which the cause is unintentional, e.g. motor vehicle, falls, burns, etc.





VIOLENCE

Any injury for which the cause is intentional, e.g. gunshot wounds, stab wounds, etc.




Weekly Visits to Sentinel Sites for Violence by Age Groups 2024 vs. Weekly **Threshold** 800 700 600 Number of Visits 500 400 300 200 100 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 Epidemiological Week <5 y.o ≥5 y.o Epi Threshold <5 y/o - Epi Threshold ≥5y/o

GASTROENTERITIS

Inflammation of the stomach and intestines, typically resulting from bacterial toxins or viral infection and causing vomiting and diarrhoea.









INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SUR VEILLANCE-30 sites. Actively pursued



CLASS ONE NOTIFIABLE EVENTS

ISSN 0799-3927

			Confirm	ed YTD ^α	AFP Field Guides from		
	CLASS 1 E	EVENTS	CURRENT YEAR 2024	PREVIOUS YEAR 2023	WHO indicate that for an effective surveillance system, detection rates for		
	Accidental F	Poisoning	235β	386^{β}	AFP should be 1/100,000 population under 15 years old (6 to 7) cases annually. ——————————————————————————————————		
1	Cholera		0	0			
ANC	Severe Deng	gue ^y	See Dengue page below	See Dengue page below			
NATIONAL /INTERNATIONAL INTEREST	COVID-19 ((SARS-CoV-2)	700	3829			
RN. EST	Hansen's Di	sease (Leprosy)	0	0			
L /INTERN INTEREST	Hepatitis B		29	63			
ÄĘ	Hepatitis C		4	30			
√NO	HIV/AIDS		NA	NA	Fever data include Dengue		
ATI	Malaria (Im	ported)	4	3	related deaths;		
Z	Meningitis		14	29	δ Figures include all deaths		
	Monkeypox		0	3	associated with pregnancy		
EXOTIC/ UNUSUAL	Plague		0	0	reported for the period.		
\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.	Meningococ	cal Meningitis	0	0	^ε CHIKV IgM positive cas θ Zika PCR positive cases		
H IGH MORBIDITY, MORTALITY	Neonatal Te	tanus	0	0			
H I ORB ORT	Typhoid Fev	ver	0	0	^β Updates made to prior weeks.		
M	Meningitis H	H/Flu	1	2	α Figures are cumulative totals for all epidemiologic		
	AFP/Polio		0	0			
	Congenital F	Rubella Syndrome	0	0	weeks year to date.		
	Congenital S	Congenital Syphilis		0			
MES	Fever and Rash	Measles	0	0			
RAM		Rubella	0	0			
.00G	Maternal De	Maternal Deaths ^δ		60			
SPECIAL PROGRAMM	Ophthalmia	Neonatorum	180	167			
	Pertussis-lik	Pertussis-like syndrome		0			
	Rheumatic F	ever	0	0			
	Tetanus		0	0			
	Tuberculosis	S	33	66			
	Yellow Feve		0	0			
	Chikunguny	aε	0	0			
	Zika Virus ^θ		0	0	NA- Not Available		







INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL **ACTIVE** SUR VEILLANCE-30 sites. Actively pursued




SENTINEL REPORT- 78 sites. Automatic reporting

Comments

COVID-19 Surveillance Update

CASES	EW 50	Total		
Confirmed	3	157430		
Females	3	90708		
Males	0	66719		
Age Range	40 to 82 years old	1 day to 108 years		
* 2				

- * 3 positive cases had no gender specification
- * PCR or Antigen tests are used to confirm cases
- * Total represents all cases confirmed from 10 Mar 2020 to the current Epi-Week.




COVID-19 Outcomes


Outcomes	EW 50	Total
ACTIVE *2 weeks*		6
DIED – COVID Related	0	3874
Died - NON COVID	0	394
Died - Under Investigation	0	143
Recovered and discharged	0	103226
Repatriated	0	93
Total		157430

- *Vaccination programme March 2021 YTD
- * Total as at current Epi week


3310 COVID-19 Related Deaths since March 1, 2021 – YTD Vaccination Status among COVID-19 Deaths



COVID-19 Parish Distribution and Global Statistics



COVID-19 WHO Global Statistics EW 47-50, 2024				
Epi Week	Confirmed Cases	Deaths		
47	44300	709		
48	47500	616		
49	49500	622		
50	50400	505		
Total (4weeks)	191700	2452		



6 NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SUR VEILLANCE-30 sites. Actively pursued




NATIONAL SURVEILLANCE UNIT **INFLUENZA REPORT**

 $\overline{EW}\,\overline{50}$


December 8, 2024 – December 14, 2024 Epidemiological Week 50

	EW 50	YTD
SARI cases	16	397
Total Influenza positive Samples	11	239
Influenza A	11	234
H3N2	0	46
H1N1pdm09	11	188
Not subtyped	0	0
Influenza B	0	5
B lineage not determined	0	0
B Victoria	0	5
Parainfluenza	0	0
Adenovirus	0	0
RSV	0	236



Epi Week Summary

During EW 50, sixteen (16) SARI admissions were reported.




Caribbean Update EW 50

Caribbean: ILI cases have shown a slight increase, linked to a rise in positive RSV cases. In constrast, SARI cases remain at low levels. Influenza activity has increased, with circulation reported in several countries across the subregion, predominantly A(H1N1)pdm09. RSV activity remains high but is showing a decline over the past four EWs. SARS-CoV-2 activity remains low throughout the subregion.

By country: Over the past four EWs, influenza activity has been reported in Barbados, Saint Lucia, Jamaica and the Cayman Islands. Additionally, RSV activity has been detected in Belize, the Dominican Republic, Jamaica, Barbados, Guyana and Saint Vincent and the Grenadines.

(taken from PAHO Respiratory viruses weekly report) https://www.paho.org/en/influenza-situation-report



NOTIFICATIONS-All clinical



INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SUR VEILLANCE-30 sites. Actively pursued






Dengue Bulletin

December 8, 2024 – December 14, 2024 Epidemiological Week 50

Epidemiological Week 50





Reported suspected, probable and confirmed dengue with symptom onset in week 50 of 2024


	2024*		
	EW 50	YTD	
Total Suspected, Probable & Confirmed Dengue Cases	5	2034	
Lab Confirmed Dengue cases	0	43	
CONFIRMED Dengue Related Deaths	0	2	

Symptoms of Dengue fever Febrile phase Critical phase sudden-onset fever hypotension headache pleural effusion mouth and nose ascites bleeding gastrointestinal bleeding muscle and joint pains Recovery phase altered level of vomiting consciousness seizures rash itching diarrhea slow heart rate

Points to note:

- Dengue deaths are reported based on date of death.
- *Figure as at December 24, 2024
- Only PCR positive dengue cases are reported as confirmed.
- IgM positive cases are classified as presumed dengue.

Suspected, probable and confirmed dengue cases for 2022 - 2024 versus monthly mean, alert, and epidemic thresholds (2007-2022)



NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SUR VEILLANCE-30 sites. Actively pursued





December 27, 2024 ISSN 0799-3927

RESEARCH PAPER

Abstract

NHRC-23-P09

A comparison of the levels of depressive and anxiety symptoms among healthcare workers and patients, at the University Hospital of the West Indies (UHWI), Jamaica, during the Coronavirus Disease (Covid-19) pandemic

O'Sullivan S¹, Lowe G¹, Gibson R¹

¹University of the West Indies, Mona, Jamaica

Objectives: 1) To compare the levels of anxiety and depression among patients and healthcare workers (HCWs) from the frontline area with those from the non-frontline areas. 2) To evaluate the association between socio-demographic and clinical factors among patients and HCWs, with higher levels of anxiety and depression.

Methods: A cross-sectional design was conducted. Participants were given the Brief Screen for Depression (BSD), the Generalized Anxiety Disorder 7 item (GAD-7) scale and the Visual Analogue Scale for anxiety (VSA-A), as well as a demographic and pandemic-related behaviours data collection questionnaire, to complete. Relationships between the socio-demographic, depressive and anxiety symptoms were assessed using t-tests, Spearman Correlation and Multiple Linear Regression Analyses.

Results: A sample of 360 participants was obtained. There were significant correlations between levels of depressive and anxiety symptoms with having a previous Covid-19 infection, time spent thinking about Covid-19, concerns about contracting Covid-19 and concern about spreading the Covid-19 virus. Additionally, regression analyses suggested that having a previous Covid-19 infection, concern about contracting Covid-19 infection and being in a frontline area, were most predictive of higher symptoms among patients. In HCWs, having a chronic illness, spending more time thinking about Covid-19, working in a frontline area and concern about contracting Covid-19 appeared to be most predictive of anxiety symptoms.


Conclusion: Multiple sociodemographic factors appear to be associated significantly with higher depressive and anxiety symptoms in patients and HCWs. These findings will help to fill the knowledge gap in the mental health consequences of Covid-19, in the Jamaican population.



The Ministry of Health and Wellness

15 Knutsford Boulevard, Kingston 5, Jamaica
Tele: (876) 633-7924

Email: surveillance@moh.gov.jm





INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SUR VEILLANCE-30 sites. Actively pursued

